Verisign INC/CA cash flow statement VRSN

In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, Verisign INC/CA generated $268.3 million of cash from operations, down 12.8% from the same quarter a year earlier. It spent $7.6 million on capital expenditures. That left free cash flow of $260.7 million. The company returned $73.0 million in dividends and $193.2 million in share buybacks to shareholders.

USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the same quarter a year earlier.

Line
TTM
Sep 30, 2026
Q3 FY2026
Sep 30, 2026
Q2 FY2026
Jun 30, 2026
Q1 FY2026
Mar 31, 2026
Q4 FY2025
Dec 31, 2025
Q3 FY2025
Sep 30, 2025
Q2 FY2025
Jun 30, 2025
Q1 FY2025
Mar 31, 2025
Q4 FY2024
Dec 31, 2024
Operating
Depreciation and amortization
26
-20.4%
7
-6.8%
7
-20.5%
6
-28.1%
7
-23.9%
7
-18.9%
8
-10.8%
9
-9.2%
9
-15.4%
Stock-based compensation
77
+13.3%
20
+10.3%
19
+22.0%
19
+9.1%
18
+12.6%
18
+16.5%
16
+11.2%
18
+15.9%
16
+8.2%
Operating cash flow
1,062
+2.8%
268
-12.8%
232
+14.4%
272
-6.5%
290
+25.1%
308
+21.4%
202
+26.2%
291
+13.2%
232
+13.4%
Investing
Capital expenditures
38
+37.1%
8
+61.7%
19
+141.0%
7
+24.1%
4
-52.6%
5
-16.1%
8
-15.2%
6
+52.6%
10
+90.0%
Investing cash flow
76
+476.1%
-89
+14.5%
-131
+38.4%
187
-41.1%
108
+624.2%
-104
-271.9%
-213
+14.8%
318
-36.0%
-21
-119.9%
Financing
Dividends paid
292
73
+1.4%
74
+2.1%
74
71
72
72
—
—
Stock buybacks
874
-1.7%
193
-11.7%
201
+20.7%
225
-6.7%
254
-3.0%
219
-27.8%
167
-57.3%
242
-10.4%
262
+16.3%
Financing cash flow
-1,166
-11.3%
-813
-184.1%
264
+204.9%
-291
-21.3%
-326
-20.3%
-286
+4.3%
-251
+35.7%
-240
+8.3%
-270
-19.5%
Change in cash
Effect of exchange rate
0
+150.0%
-0
0
-25.0%
0
+200.0%
-0
+88.9%
0
-100.0%
0
+300.0%
-0
+25.0%
-1
-280.0%
Net change in cash
-29
+19.9%
-634
-667.7%
364
+239.4%
169
-54.2%
72
+219.6%
-83
-643.4%
-261
+45.5%
369
-25.0%
-61
-173.5%
Free cash flow
1,024
+1.9%
261
-14.0%
213
+9.3%
265
-7.1%
285
+28.4%
303
+22.3%
195
+28.8%
286
+12.6%
222
+11.4%
Per share
Free cash flow per share
11.18
+5.1%
2.88
-10.9%
2.34
+12.8%
2.89
-4.1%
3.07
+32.0%
3.24
+27.1%
2.07
+35.6%
3.01
+19.9%
2.32
+19.0%
Dividend per share
3.20
0.81
+5.2%
0.81
+5.2%
0.81
0.77
0.77
0.77
—
—
Shareholder returns
Returned to shareholders
1,166
266
275
300
326
291
239
242
262
Share of free cash flow
113.92%
102.11%
129.23%
112.97%
114.17%
95.94%
122.70%
84.66%
118.15%
Ratios
Free cash flow margin
59.12%
58.85%
48.96%
61.83%
67.04%
72.30%
47.50%
70.97%
56.15%
Capital expenditures to revenue
2.20%
1.72%
4.33%
1.68%
1.06%
1.12%
1.90%
1.44%
2.40%
Stock-based compensation to revenue
4.43%
4.58%
4.46%
4.45%
4.21%
4.39%
3.88%
4.35%
4.02%
Cash conversion
—
1.26x
1.07x
1.27x
—
1.45x
0.98x
1.46x
—
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.

Company profile

Industry
Services-Computer Programming Services (SIC 7371)
Listed as
VRSN (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Reston, VA
SEC filer status
Large accelerated filer
SEC CIK
1014473

Other Services-Computer Programming Services companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.